title: Single-dose pharmacokinetics of porcine factor VIII (Hyate C).
abstract: The objective was to establish the pharmacokinetic properties of porcine factor VIII (pFVIII) at three different doses in a single patient. The patient, born in 1952, had severe haemophilia A and developed an inhibitor to human FVIII (hFVIII) in 1966 aged 14 years. He was first treated with pFVIII in 1980. Apart from a short period of treatment with hFVIII in 1998 which resulted in the reappearance of the inhibitor, pFVIII has been constantly used since 1984. No inhibitor against human or porcine FVIII had been recordable over the 2-year period prior to the study. Three separate pharmacokinetic studies were performed using a washout period of 72 h and doses of 10 U kg (-1), 25 U kg (-1), or 50 U kg (-1), respectively, with sampling at preinfusion, then at 15 and 30 min and 1, 3, 6, 9, 12 and 24 h postinfusion. The FVIII levels were measured using both plasma derived one stage APTT based assay and chromogenic assay. The results were computed using a model-independent analysis and a model-dependent analysis. The respective clearances (mL h(-1)kg(-1)) at doses 50 U, 25 U or 10 U kg (-1) were 1.32, 1.33 1.8 (bioassay) and 2.54, 2.93, 9.43 (chromogenic). The respective half-lives (h) at doses 50 U, 25 U, and 10 U kg (-1) were 23.71, 16.54, 25.17 (bioassay) and 15.71, 17.39, and 10.66 (chromogenic). The respective recoveries (u dL(-1)/u kg(-1)) at doses 50 U, 25 U, and 10 U kg (-1) were 2.32, 2.44, 2.7 (bioassay) and 1.42, 1.16 and 0.9 (chromogenic). It was found that the two compartment model best fitted the curves of the bioassay and a one compartmental model best fitted the curves of the chromogenic assay. The pharmacokinetic studies are the first to be performed at different dose levels and using different assay methods for pFVIII. Using the bioassay, they show a long half-life and high recovery compared to hFVIII. The differences between the bioassay and the chromogenic assay reflect their different biological basis and are of relevance when potency labelling is performed using chromogenic assay (European Pharmacopeia).
authors.affiliation: Haemophilia Centre and Haemostasis Unit, Royal Free Hospital, Pond Street, London NW3 2QG, UK.
authors.forename: C
authors.initials: C
authors.lastname: Hermans
authors.forename: D
authors.initials: D
authors.lastname: Owens
authors.forename: P
authors.initials: P
authors.lastname: Lilley
authors.forename: G
authors.initials: G
authors.lastname: Longo
authors.forename: M
authors.initials: M
authors.lastname: Morfini
authors.forename: C A
authors.initials: CA
authors.lastname: Lee
mesh_terms: D000818:Animals; D002863:Chromogenic Compounds; D005169:Factor VIII / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006207:Half-Life; D006467:Hemophilia A / Q000188:drug therapy; D006801:Humans; D007108:Immune Tolerance; D007700:Kinetics; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D015233:Models, Statistical; D010314:Partial Thromboplastin Time; D010599:Pharmacokinetics; D013552:Swine
chemical_list: D002863:Chromogenic Compounds; D005169:Factor VIII